{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:20:29Z","timestamp":1787228429462,"version":"build-2736575974"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Headache is a common adverse drug reaction (ADR) across diverse therapeutic classes, yet systematic evaluations of drug-associated headaches in real-world settings are limited. This study aimed to explore the association between various medications and the reporting of headache as an ADR using the FDA-Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective disproportionality analysis using FAERS data from Q1-2018 to Q4-2024. Duplicate reports were removed per FDA guidelines. Reports with headache as an adverse event and drugs classified as Primary Suspect were included. Disproportionality metrics \u2014 Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)\u2014were calculated to identify signals. Drugs were classified according to the Anatomical Therapeutic Chemical(ATC) classification system, and time-to-onset analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 313,166 headache-associated cases were identified. Females (66.66%) and patients aged 51\u201365 years (21.35%) were most commonly affected. The drugs with the highest headache risk based on ROR included glecaprevir\/pibrentasvir (ROR\u2009=\u200910.445), sofosbuvir\/velpatasvir (ROR\u2009=\u20099.729), and eptinezumab-jjmr (ROR\u2009=\u20096.775). Top frequently reported drugs were apremilast, treprostinil, and adalimumab. Calcium homeostasis agents (ROR\u2009=\u20096.268) and systemic antivirals (ROR\u2009=\u20094.259) emerged as the ATC classes with the highest headache signal strength. Early-onset headaches (\u22647days) were particularly associated with ofatumumab and fingolimod. Late-onset headaches (&amp;gt;90days) were linked to treprostinil and infliximab-dyyb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large-scale pharmacovigilance study identifies multiple drugs and therapeutic classes with significant associations to headache as an ADR. These findings highlight the need for proactive headache monitoring, particularly during early treatment phases, and warrant further prospective investigations to understand mechanisms and preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2025.1670648","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:22:15Z","timestamp":1762496535000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018\u20132024)"],"prefix":"10.3389","volume":"6","author":[{"given":"Abdulaziz Ibrahim","family":"Alzarea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azfar Athar","family":"Ishaqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Salah","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel Awad","family":"Alsaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tauqeer Hussain","family":"Mallhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Orayj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan M.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan H.","family":"Alhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami I.","family":"Alzarea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Awad","family":"Alsaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1501749","DOI":"10.3389\/fneur.2024.1501749","article-title":"Headache disorders: a persistent public health challenge for the under 50s","volume":"15","author":"Meng","year":"2024","journal-title":"Front Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J Headache Pain"},{"key":"B3","volume-title":"\u201cChronic Headaches,\u201d in StatPearls [Internet]","author":"Murphy","year":"2023"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.3390\/ijerph18052674","article-title":"Headache as an adverse reaction to the use of medication in the elderly: a pharmacovigilance study","volume":"18","author":"Monteiro","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","article-title":"Medication overuse headache","volume":"9","author":"Ashina","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.clineuro.2012.02.041","article-title":"Headaches related to psychoactive substance use","volume":"114","author":"Beckmann","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/187152412802430147","article-title":"Central nervous system acting drugs in treatment of migraine headache","volume":"12","author":"Samsam","year":"2012","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1093\/eurheartj\/ehad363","article-title":"Migraine and cardiovascular disease: what cardiologists should know","volume":"44","author":"Kalkman","year":"2023","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1476-5381.2010.00643.x","article-title":"Headache-type adverse effects of NO donors: vasodilation and beyond","volume":"160","author":"Bagdy","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40263-020-00706-8","article-title":"Targeting BKCa channels in migraine: rationale and perspectives","volume":"34","author":"Al-Karagholi","year":"2020","journal-title":"CNS Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.encep.2016.05.006","article-title":"Antidepressant and tolerance: determinants and management of major side effects","volume":"42","author":"David","year":"2016","journal-title":"Encephale"},{"key":"B12","author":"Chu","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.neurol.2021.07.006","article-title":"Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment","volume":"177","author":"Ducros","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/08971900231167925","article-title":"The art of hormone replacement therapy (HRT) in menopause management","volume":"37","author":"Cameron","year":"2024","journal-title":"J Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","article-title":"The evolution of medication overuse headache: history, pathophysiology and clinical update","volume":"35","author":"Sun-Edelstein","year":"2021","journal-title":"CNS Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/head.14453","article-title":"An exploratory study evaluating the 30 medications most commonly associated with headaches in the FDA adverse event reporting system","volume":"63","author":"Musialowicz","year":"2023","journal-title":"Headache"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41598-025-89272-x","article-title":"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0317680","DOI":"10.1371\/journal.pone.0317680","article-title":"Drug-induced autoimmune-like hepatitis: a disproportionality analysis based on the FAERS database","volume":"20","author":"Ye","year":"2025","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the national pharmacovigilance centre in The Netherlands: an explorative observational study","volume":"85","author":"De Vries","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.therap.2022.10.002","article-title":"Sex differences in adverse drug reactions: are women more impacted?","volume":"78","author":"Lacroix","year":"2023","journal-title":"Therapies"},{"key":"B26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12877-022-03027-1","article-title":"Characteristics and comorbidities of headache in patients over 50 years of age: a cross-sectional study","volume":"22","author":"Togha","year":"2022","journal-title":"BMC Geriatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40263-018-0522-8","article-title":"Polypharmacy among headache patients: a cross-sectional study","volume":"32","author":"Ferrari","year":"2018","journal-title":"CNS Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e31183","DOI":"10.1097\/MD.0000000000031183","article-title":"Safety and efficacy of sofosbuvir-velpatasvir: a meta-analysis","volume":"101","author":"Ren","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s40121-024-00968-5","article-title":"Real-world efficacy and safety of universal 8-week glecaprevir\/pibrentasvir for treatment-naive patients from a nationwide HCV registry in Taiwan","volume":"13","author":"Yang","year":"2024","journal-title":"Infect Dis Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","article-title":"Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system","volume":"14","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4877","article-title":"Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study","volume":"38","author":"Lewiecki","year":"2023","journal-title":"J Bone Miner Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.adengl.2020.12.016","article-title":"Multidisciplinary management of the adverse effects of apremilast","volume":"112","author":"Tello","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab For maintenance of clinical response and remission in patients with crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e12420","DOI":"10.7759\/cureus.12420","article-title":"Disorders of calcium metabolism: hypocalcemia and hypercalcemia","volume":"13","author":"Tinawi","year":"2021","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/medicina55080407","article-title":"Hypocalcemia and vitamin D deficiency amongst migraine patients: a nationwide retrospective study","volume":"55","author":"Patel","year":"2019","journal-title":"Medicina (B Aires)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1759720X09339551","article-title":"Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture","volume":"1","author":"Mulgund","year":"2009","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"20420188221099344","DOI":"10.1177\/20420188221099344","article-title":"Calcitonin: current concepts and differential diagnosis","volume":"13","author":"Kiriakopoulos","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/bs.seda.2022.09.006","article-title":"Antiviral drugs","volume":"44","author":"Samuel","year":"2022","journal-title":"Side Eff Drugs Annu"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1515730","DOI":"10.3389\/fimmu.2025.1515730","article-title":"The real-world safety of ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/head.12526","article-title":"Persistent headache in patients with multiple sclerosis starting treatment with fingolimod","volume":"55","author":"Fragoso","year":"2015","journal-title":"Headache"},{"key":"B48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jdv.14598","article-title":"Apremilast in psoriasis\u2013a prospective real-world study","volume":"32","author":"Vujic","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","article-title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/ane.13144","article-title":"Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases","volume":"140","author":"Graf","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/14737175.2024.2321921","article-title":"A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder","volume":"24","author":"Abbas","year":"2024","journal-title":"Expert Rev Neurother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1542\/peds.107.1.e10","article-title":"Placebo-controlled evaluation of amphetamine mixture\u2014dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects","volume":"107","author":"Ahmann","year":"2001","journal-title":"Pediatrics"},{"key":"B56","author":"Fischer","year":""},{"key":"B57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1468-2982.2009.01913.x","article-title":"Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study","volume":"30","author":"Scher","year":"2010","journal-title":"Cephalalgia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pain.2011.08.018","article-title":"Risk factors for medication-overuse headache: an 11-year follow-up study. The nord-tr\u00f8ndelag health studies","volume":"153","author":"Hagen","year":"2012","journal-title":"Pain"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/ene.12732","article-title":"Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic-based study in China","volume":"22","author":"He","year":"2015","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1670648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:22:16Z","timestamp":1762496536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2025.1670648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":59,"alternative-id":["10.3389\/fpain.2025.1670648"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2025.1670648","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1670648"}}